Dear Members Of The Acorda Community:

We aim to grow Acorda into the preeminent biopharmaceutical company delivering innovative therapies for people with neurological disorders, and are building on three pillars to drive long-term value creation:

• Advancing our diversified clinical pipeline to approval and commercialization;
• Acquiring assets that leverage our core competencies in neurology; and
• Continuing to grow sales in multiple sclerosis of AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.